Experience

Davis Polk advised Coloplast A/S in connection with its strategic equity investment in Francis Medical, Inc.Coloplast A/S is a Danish medical device company that develops products and…

Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion,…

Davis Polk is advising JP Morgan Securities LLC and Lazard as financial advisers to Aimmune Therapeutics in connection with its $2.6 billion sale to Sociétés des Produits Nestlé, S.A., a…

Davis Polk is advising Amwell on its agreement to form a multi-year, strategic partnership with Google Cloud to deliver transformative telehealth solutions across the global healthcare…

Davis Polk is advising JP Morgan Securities LLC as financial adviser to NN, Inc. in connection with the $825 million sale of its Life Sciences division to affiliates of American Securities…

Davis Polk is advising Bristol Myers Squibb on its acquisition of Forbius. The transaction includes an upfront payment and future success-based milestone payments. The transaction is…

Davis Polk is advising Novo Nordisk A/S on its acquisition of Corvidia Therapeutics Inc. for an upfront payment of $725 million in cash. Total payments to Corvidia Therapeutics shareholders…

Davis Polk is advising J M Smith Corporation in connection with the sale of its technologies division, Smith Technologies, to private equity sponsor Francisco Partners, pursuant to a…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $380 million acquisition of HemaCare Corporation. The proposed purchase price equates to $25.40…

Davis Polk is advising Roche on its acquisition of Promedior, Inc. Under the terms of the merger agreement, Roche will make an upfront cash payment of $390 million, plus additional…